InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（0 笔）
内部人交易记录
首席执行官已披露买入
0
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the full record of transactions filed by Buell Jennifer, 首席执行官. Insider active across 2 companies, notably MiNK Therapeutics, Inc.. Aggregated, 19 disclosures have been logged. History available since 30 June 2021. The latest transaction was filed on 2 January 2026 (Retenue fiscale). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Buell Jennifer
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报19 总计
10,024 股@ US$11.120.18% mcap28.7% 占其流量Common StockSEC:0001193125-26-012914:0
31,474 股@ US$11.1227.0% 占其流量Common StockSEC:0001193125-26-004799:0
5,351 股@ US$15.360.13% mcap21.3% 占其流量Common StockSEC:0001193125-25-230098:0
18,229 股@ US$15.3629.7% 占其流量Common StockSEC:0001193125-25-201376:0
581 股@ US$3.111.4% 占其流量Common StockSEC:0000950170-25-064636:0
869 股@ US$2.081.4% 占其流量Common StockSEC:0000950170-25-063522:0
1,159 股@ US$1.561.4% 占其流量Common StockSEC:0000950170-25-052895:0
1,123 股@ US$1.611.5% 占其流量Common StockSEC:0000950170-25-046050:0
409 股@ US$2.350.8% 占其流量Common StockSEC:0000950170-25-043817:0
545 股@ US$3.321.5% 占其流量Common StockSEC:0000950170-25-037127:0
626 股@ US$3.321.7% 占其流量Common StockSEC:0000950170-25-033526:0
516 股@ US$3.501.5% 占其流量Common StockSEC:0000950170-25-022204:0
270 股@ US$3.570.8% 占其流量Common StockSEC:0000950170-25-013409:0
776 股@ US$3.572.3% 占其流量Common StockSEC:0000950170-25-010023:0
695,750 股Common StockSEC:0000950170-23-053381:0
25,000 股@ US$1.15383.7% 占其流量Common StockSEC:0000950170-23-051760:0
695,750 股Common StockSEC:0000950170-23-050807:0
171,990 股@ US$2.3251.2% 占其流量Common StockSEC:0000899243-23-001620:0
10,597 股@ US$5.4974.9% 占其流量Common StockSEC:0000899243-21-027356:0
19 条申报中的 19 条
About Buell Jennifer
Jennifer Buell is the Chief Executive Officer and President at MiNK Therapeutics, Inc. and AGENUS INC. She leads the strategic operations of these companies, focusing on the development of immunological therapies. Her experience in the biopharmaceutical sector is a significant asset in achieving growth objectives.
